Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 24, 2022

Sintilimab vs Placebo Combined With Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic ESCC

BMJ: British Medical Journal


Additional Info

BMJ: British Medical Journal
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
BMJ 2022 Apr 19;377(xx)e068714, Z Lu, J Wang, Y Shu, L Liu, L Kong, L Yang, B Wang, G Sun, Y Ji, G Cao, H Liu, T Cui, N Li, W Qiu, G Li, X Hou, H Luo, L Xue, Y Zhang, W Yue, Z Liu, X Wang, S Gao, Y Pan, MP Galais, A Zaanan, Z Ma, H Li, Y Wang, L Shen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading